Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Infectious Diseases
Volume 2017, Article ID 6093695, 3 pages
https://doi.org/10.1155/2017/6093695
Case Report

A Case of Fulminant Meningococcemia: It Is All in the Complement

1Division of Infectious Disease, Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA
2Denver Health and Hospital Authority, Denver, CO, USA
3Division of Internal Medicine, Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA
4Division of Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA

Correspondence should be addressed to Kellie L. Hawkins; ude.revnedcu@snikwah.eillek

Received 5 April 2017; Revised 24 May 2017; Accepted 14 June 2017; Published 20 July 2017

Academic Editor: Alexandre Rodrigues Marra

Copyright © 2017 Kellie L. Hawkins et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Takeda, T. Miyata, K. Kawagoe et al., “Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria,” Cell, vol. 73, no. 4, pp. 703–711, 1993. View at Publisher · View at Google Scholar · View at Scopus
  2. R. Kelly, S. Richards, P. Hillmen, and A. Hill, “The pathophysiology of paroxysmal nocturnal hemoglobinuria and treatment with eculizumab,” Therapeutics and Clinical Risk Management, vol. 5, no. 1, pp. 911–921, 2009. View at Google Scholar · View at Scopus
  3. P. Hillmen, N. S. Young, J. Schubert et al., “The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria,” The New England Journal of Medicine, vol. 355, no. 12, pp. 1233–1243, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. M. E. Patton, D. Stephens, K. Moore, and J. R. MacNeil, “Updated Recommendations for Use of MenB-FHbp Serogroup B Meningococcal Vaccine — Advisory Committee on Immunization Practices, 2016,” MMWR. Morbidity and Mortality Weekly Report, vol. 66, no. 19, pp. 509–513, 2017. View at Publisher · View at Google Scholar
  5. “FDA Drug Safety and Risk Management Advisory Committee. Soliris® (eculizumab),” 2014, https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafetyandRiskManagementAdvisoryCommittee/UCM426664.pdf.
  6. A. Bouts, L. Monnens, J.-C. Davin, G. Struijk, and L. Spanjaard, “Insufficient protection by Neisseria meningitidis vaccination alone during eculizumab therapy,” Pediatric Nephrology, vol. 26, no. 10, pp. 1919-1920, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. R. A. Brodsky, N. S. Young, E. Antonioli et al., “Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria,” Blood, vol. 111, no. 4, pp. 1840–1847, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. A. C. Cohn, J. R. MacNeil, T. A. Clark et al., “Centers for Disease Control (CDC). Prevention and Control of Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP),” MMWR Recomm Rep, vol. 62, no. RR-2, pp. 1–28, 2013. View at Google Scholar
  9. A. O. Applegate, V. C. Fong, K. Tardivel, S. A. Lippold, and S. Zarate, “Notes from the Field: Meningococcal Disease in an International Traveler on Eculizumab Therapy ? United States, 2015,” MMWR. Morbidity and Mortality Weekly Report, vol. 65, no. 27, pp. 696-697, 2016. View at Publisher · View at Google Scholar
  10. N. Cullinan, K. M. Gorman, M. Riordan, M. Waldron, T. H. J. Goodship, and A. Awan, “Case report: Benefits and challenges of long-term eculizumab in atypical hemolytic uremic syndrome,” Pediatrics, vol. 135, no. 6, pp. e1506–e1509, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. M. A. Rey-Mugica, “Meningococcaemia durante el tratamiento con Eculizumab,” Enferm Infec Microbol Clin, 2012. View at Google Scholar
  12. G. H. Struijk, A. H. M. Bouts, G. T. Rijkers, E. A. C. Kuin, I. J. M. Ten Berge, and F. J. Bemelman, “Meningococcal sepsis complicating eculizumab treatment despite prior vaccination,” American Journal of Transplantation, vol. 13, no. 3, pp. 819-820, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. F. Alashkar, C. Vance, D. Herich-Terhürne, N. Preising, U. Dührsen, and A. Röth, “Serologic response to meningococcal vaccination in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with the terminal complement inhibitor eculizumab,” Annals of Hematology, vol. 96, no. 4, pp. 589–596, 2017. View at Publisher · View at Google Scholar